We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are ...

Zyprexa in 1996 for schizophrenia, and Cymbalta in 2004 for depression and anxiety. In the field of diabetes care, Lilly’s Humalog and Trulicity have been major revenue drivers. Eli Lilly and ...

Lilly is known for its clinical depression drugs Prozac (1986), Cymbalta (2004), and its antipsychotic medication Zyprexa (1996 ... one insider made 24 sales of Eli Lilly shares.

Paul spent 17 years at Eli Lilly, where he held roles including ... At Lilly, Paul helped develop the company’s mental health blockbusters, Zyprexa and Cymbalta, and helped oversee development ...

Rounding out the top 10 were Procrit (Johnson & Johnson), ranked fourth with $3.3 billion in 2003 US sales, up 3.7% from 2002; Zyprexa (Eli Lilly), ranked fifth with $3.2 billion, up 6.6% ...

J Midwifery Womens Health. 2007;52(1):3-13. There are no epidemiologic exposure data reported specifically for women with bipolar disorder who take anticonvulsants during pregnancy. Most data ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.